Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant plus adjuvant camrelizumab versus adjuvant camrelizumab alone in newly diagnosed resectable glioblastoma
ChiCTR2000031405Phase 4Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of camrelizumab in glioblastoma (GBM) (2 arms), sponsored by Fudan University Shanghai Cancer Center. Primary endpoint: Overall survival. Planned start May 2020; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000031405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031405.